Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 11:36 PM
Ignite Modification Date:
2025-12-25 @ 9:26 PM
NCT ID:
NCT02795156
Group ID:
EG001
Title:
Arm 2
Description:
Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
Afatinib: 40 mg orally once daily for each 28-day cycle
Regorafenib: 160 mg orally once daily for the first 21-days of each 28-day
Cabozantinib: 60 mg orally once daily for each 28-day cycle
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
6
Serious Number At Risk:
10
Other Number Affected:
10
Other Number At Risk:
10
Study:
NCT02795156
Results Section:
NCT02795156
Adverse Events Module:
NCT02795156